Singapore's policy quirk lures bank funding rush



* Singapore dollar debt pricing attractive vs U.S. dollar markets

* Private banks doing most of the buying

* Trend can continue as broad macro mood sours - bankers

By Tom Westbrook and Rae Wee

SINGAPORE, July 12 (Reuters) - Global banks are rushing to sell bonds in Singapore, where unique monetary settings have opened a favourable borrowing window that puts the city-state's debt markets on course for the biggest year of bank-capital raising in more than a decade.

Singapore's central bank manages policy via its currency, rather than short-term rates, and one consequence has been the benchmark Singapore Overnight Rate Average (SORA) lagging a rise in comparable borrowing costs for U.S. dollars.

Unlike other low-rate destinations in Europe or Japan, the Monetary Authority of Singapore is also keen on keeping the Singapore dollar SGD=D3 steady, reducing currency risk, and investor appetite has been strong.

Almost S$12 billion ($8.5 billion) has been raised in Singapore's debt markets from Jan. 1 to July 6, the largest for the period since 2019, according to Refinitiv data, with June the biggest month for issuance by value since Sept. 2021.

About half of the S$3.5 billion raised in June and a fifth of the year-to-date figure are "Tier 2" notes, issued by banks for reserve capital requirements - the biggest slice of this type of debt that Singapore has seen in over 10 years.

"Debt markets here are still quite well behaved, rates have not risen significantly," Daryl Ho, senior investment strategist at Singapore's DBS Bank, said at a briefing, in contrast to deteriorating conditions in bigger markets.

"Naturally, you'll attract a lot of issuers."

Through June, SORA SORA=MAST , a volume-weighted calculation on unsecured interbank loans and a benchmark for longer rates, averaged about 1% against an average of just over 1.2% for overnight dollar LIBOR USDONFSR= .

Private banks have led solid investor demand. UOB, the bookrunner for a S$900 million Tier-2 note for HSBC in June GB249165417= , said it was oversubscribed - with private banks the biggest buyers - and that 5.25% was a competitive price.

"The Singapore dollar trade was priced about 20 to 25 basis points tighter than what they would have achieved in the U.S. dollar market," said Carolyn Tan, UOB's head of debt capital markets for bonds. HSBC HSBA.L had no comment.

Lenders such as BNP Paribas BNPP.PA , ABN Amro ABNd.AS and Barclays BARC.L also sold debt in Singapore dollars recently. Barclays' S$450 million alternative Tier-1 deal last week had a coupon of 8.3% GB249845434= , against a coupon of 8.875% on £1.25 billion ($1.5 billion) raised GB249248282= a week earlier.

"I would expect a lot of bank treasurers would look at this market very closely," said Ken Wei Wong, Barclays' head of Asia-Pacific fixed income syndicate.

"There is momentum ... given the dislocation in G3 (currencies)."

Money-market futures are priced for that to continue, with three-month eurodollar futures 0#ED: , which track the cost of borrowing U.S. dollars abroad, showing traders see interest rates hitting 3% by year's end.

"Financial institutions are likely being pro-active," said Andrew Wong, vice president of credit research at OCBC Bank in Singapore.

"For now, the Singapore dollar market is relatively cheaper than other markets so as long as this dynamic holds then we expect financial institutions will continue to issue in Singapore dollars." ($1 = 1.4016 Singapore dollars) ($1 = 0.8331 pounds)
Reporting by Tom Westbrook in Singapore Additional reporting by Rae Wee Editing by Vidya Ranganathan and Sam Holmes

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Nous utilisons des cookies pour vous donner la meilleure expérience possible de notre site internet. En savoir plus ou modifier vos paramètres de cookies.

Avertissement sur les risques : votre capital est à risque. Les produits à effet de levier ne sont pas recommandés pour tous. Veuillez consulter notre Divulgation des risques